Home › Crohn's Disease › Texas › Tyler
Pag-aaral pangklinika para sa Crohn's Disease sa Tyler, TX
16 pag-aaral para sa Crohn's Disease ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Tyler (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Nagre-recruitPhase 3
- Tyler Research Institute ( Site 0294), Tyler
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Nagre-recruitPhase 3
- Tyler Research Institute ( Site 5001), Tyler
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Nagre-recruitPhase 2
- Tyler Research Institute /ID# 265545, Tyler
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Nagre-recruitPhase 3
- The University of Texas Health Science Center at Tyler, Tyler
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Nagre-recruitPhase 2/3
- Tyler Research Institute, LLC, Tyler
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Nagre-recruitPhase 2
- Tyler Research Institute, LLC, Tyler
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Nagre-recruitPhase 3
- Tyler Research Institute, Tyler
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Nagre-recruitPhase 3
- Tyler Research Institute, LLC-Site Number: 8400095, Tyler
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Nagre-recruitPhase 3
- Tyler Research Institute LLC-Site Number: 8400095, Tyler
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Nagre-recruitPhase 2
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Nagre-recruitPhase 4
- Tyler Research Institute, LLC, Tyler
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Nagre-recruitPhase 3
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Nagre-recruitPhase 3
- Tyler Research Institute, LLC, Tyler
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Nagre-recruitPhase 2
- Tyler Research Institute, LLC, Tyler
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Nagre-recruitPhase 2
- Tyler Research Institute, LLC, Tyler
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Nagre-recruitPhase 2
- Mirador Therapeutics Selected Site, Tyler
Pag-aaral para sa Crohn's Disease sa ibang lungsod
- New York City, NY35 pag-aaral
- Cleveland, OH19 pag-aaral
- St. Louis, MO19 pag-aaral
- Boston, MA19 pag-aaral
- Miami, FL19 pag-aaral
- Orlando, FL17 pag-aaral
- Houston, TX17 pag-aaral
- Atlanta, GA17 pag-aaral
- San Diego, CA15 pag-aaral
- San Antonio, TX15 pag-aaral
- Los Angeles, CA15 pag-aaral
- Philadelphia, PA13 pag-aaral
Iba pang pag-aaral sa Tyler
- Non-Small Cell Lung Cancer20 pag-aaral
- Ulcerative Colitis14 pag-aaral
- Colorectal Cancer8 pag-aaral
- Pagkabigo ng Puso8 pag-aaral
- Kanser (lahat ng uri)7 pag-aaral
- Kanser sa Ovary7 pag-aaral
- Kanser ng Endometrium6 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg6 pag-aaral
- Kanser sa Suso6 pag-aaral
- Metastatic Cancer5 pag-aaral
- Inflammatory Bowel Disease5 pag-aaral
- Chronic Lymphocytic Leukemia5 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.